Program
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001
Also written as “NEOK001” and “NEOK001 RDE”.
Its studies are mostly in Neoplasm Metastasis, led by NEOK Bio.
Furthest: phase 1, since May 21, 20261 company-led study, 1 open or runningNext primary completion: Jan 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| NEOK Bio | 11 open or running | phase 1since May 21, 2026 | May 21, 2026 | Jan 2029phase 1 · NCT07612176 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 21, 2026First study: phase 1 study in Neoplasm MetastasisFirst studyNCT07612176 · 155 planned · United States
Ahead
- Jan 2029Primary completion: phase 1 study in Neoplasm MetastasisNCT07612176
TargetBeta
“An antibody-drug conjugate (ADC) composed of a bispecific antibody directed against the tumor associated antigens (TAAs) B7-homologue 3 (B7-H3, CD276) and receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is ”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07612176Neoplasm Metastasis · United States | 1 | Recruiting | Jan 2029 | 155 |
How it is read
Names in the registry
- “NEOK001”, 1 entry
- “NEOK001 RDE”, 1 entry
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.